IBio Analyst Ratings
IBio Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 02/16/2023 | — | JMP Securities | Downgrades | Market Outperform → Market Perform | |
| 10/07/2022 | -80.45% | Cantor Fitzgerald | $2.5 → $0.17 | Downgrades | Overweight → Neutral |
| 11/29/2021 | 72.49% | JMP Securities | → $1.5 | Initiates Coverage On | → Outperform |
| 01/22/2021 | 244.99% | Cantor Fitzgerald | → $3 | Initiates Coverage On | → Overweight |
| 01/21/2021 | 244.99% | Cantor Fitzgerald | → $3 | Initiates Coverage On | → Overweight |
| 06/26/2020 | 216.24% | Alliance Global Partners | → $2.75 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变化 | 上一页/当前额定值 |
|---|---|---|---|---|---|
| 02/16/2023 | — | JMP 证券 | 降级 | 市场跑赢大盘 → 市场表现 | |
| 2022 年 7 月 10 日 | -80.45% | 坎托·菲茨杰拉德 | 2.5 美元 → 0.17 美元 | 降级 | 超重 → 中性 |
| 11/29/2021 | 72.49% | JMP 证券 | → 1.5 美元 | 开启覆盖范围 | → 跑赢大盘 |
| 01/22/2021 | 244.99% | 坎托·菲茨杰拉德 | → 3 美元 | 开启覆盖范围 | → 超重 |
| 01/21/2021 | 244.99% | 坎托·菲茨杰拉德 | → 3 美元 | 开启覆盖范围 | → 超重 |
| 06/26/2020 | 216.24% | 联盟全球合作伙伴 | → 2.75 美元 | 开启覆盖范围 | → 购买 |
What is the target price for iBio (IBIO)?
iBio（IBIO）的目标价格是多少？
The latest price target for iBio (AMEX: IBIO) was reported by JMP Securities on February 16, 2023. The analyst firm set a price target for $0.00 expecting IBIO to fall to within 12 months (a possible -100.00% downside). 2 analyst firms have reported ratings in the last year.
JMP Securities于2023年2月16日公布了iBio（美国证券交易所代码：IBIO）的最新目标股价。这家分析公司将目标价设定为0.00美元，预计IBIO将在12个月内降至-100.00％（可能下跌-100.00％）。去年，有两家分析公司公布了评级。
What is the most recent analyst rating for iBio (IBIO)?
iBio（IBIO）的最新分析师评级是多少？
The latest analyst rating for iBio (AMEX: IBIO) was provided by JMP Securities, and iBio downgraded their market perform rating.
iBio（美国证券交易所股票代码：IBIO）的最新分析师评级由JMP Securities提供，iBio下调了其市场表现评级。
When is the next analyst rating going to be posted or updated for iBio (IBIO)?
iBio（IBIO）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of iBio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for iBio was filed on February 16, 2023 so you should expect the next rating to be made available sometime around February 16, 2024.
分析师在进行了广泛的研究后得出了股票评级，包括浏览公开财务报表，与iBio的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月这样做一次，因此每家公司每年应该获得4次评级。iBio的最新评级是在2023年2月16日提交的，因此您应该预计下一个评级将在2024年2月16日左右公布。
Is the Analyst Rating iBio (IBIO) correct?
分析师评级 iBio (IBIO) 是否正确？
While ratings are subjective and will change, the latest iBio (IBIO) rating was a downgraded with a price target of $0.00 to $0.00. The current price iBio (IBIO) is trading at is $0.87, which is out of the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的iBio（IBIO）评级被下调，目标价为0.00美元至0.00美元。iBio（IBIO）目前的交易价格为0.87美元，超出了分析师的预测区间。
译文内容由第三方软件翻译。